Leonard Lichtenfeld, MD: There are all sorts of things in the Affordable Care Act that many people don’t know about, or don’t pay attention to, that certainly don’t have big constituencies. One of the issues is accountable care organizations and the concept of paying for care in a different way, and that’s still a work in progress. There are some that have been successful, and some that are not as successful. I’m familiar with one practice in particular, in which they made a concerted effort to implement the ACO model, and they ended up having to back out because they were already a high-performing practice and the rewards of doing that didn’t work—and there are all sorts of innovative models. They may be virtual ACOs. There’s a lot going on.
But there are some practical questions. What about the Center for Medicare and Medicaid Innovation? Now, some people will say, “I don’t like what the CMMI does; I don’t want them anyway.” But a lot of people happen to like what they’ve done. What about the CCMI Oncology Care Model, which has been trying to figure out a better way to pay for cancer care? What if that goes away? What do you do? I was sitting in a meeting a couple of months ago, just after the election, and started to scratch my head and say, “Well, if CMMI goes away, what happens to the Oncology Care Model?” I’ve heard nobody address that. Most people say, “Well, the CMMI model won’t go away, but it may have more Congressional oversight. It’s all part of the legislative process.”
It’s the old sausage making issue—you don’t want to watch it being made, but eventually somebody will make a decision. But there are also other agencies that may not be part of the ACA specifically, like the Agency for Healthcare Research and Quality, which looks at patient-centered outcomes research—to try to foster that. That may not be an immediate part of the ACA, but it is on the radar screen. Is that going to go away? Will we lose some of the organizations and institutions that we need to be able to understand what quality care is?
So, there are a lot of pieces to this puzzle. It was a very long act. I’ve never read it, I have no intention of reading it, and I won’t get into the famous quotation—“You’ll know what’s in it after you pass it”—but we’re still in that process: the absolute repeal coming and saying that it’s all gone. It would be a lot of work to put it back together, and there are always going to be problems. Legislation is not designed to be perfect. There’s always the regulatory piece, and then there are always the pieces that need to be fixed. We need to pay attention to all those below the radar screen issues, because they have an impact on the way that we give care.
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Federal Trade Commission (FTC) issued letters to 10 companies to warn them that certain drug patents were improperly listed; the US Department of Agriculture (USDA) will begin testing ground beef for bird flu particles; rural Americans are more likely to die early from 1 of the 5 leading causes of death than those who live in urban areas.
Read More
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More